Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Serologically-confirmed HIV and HBV infection~* Willingness to participate in a clinical trial~* No previous or current use of antiretroviral regimen~* Clinical conditions stable~* Blood creatinine less than 3 times the upper limit of normal values. HBV DNA\>1000copies/ml, Tbil\<34umol/L,ALT\<400U/L~* With clinical indications for HAART~Exclusion Criteria:~* Patient refuses to sign the consent to participate~* Unwillingness to adhere to visit schedule or maintain adherence with medications~* Illnesses so serve as to likely require hospitalization~* With other conditions that not suitable to be enrolled will be subject to medical review

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- TDF/3TC/EFV Treatment HIV/HBV Co-infection (Type: EXPERIMENTAL): TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection

Based on this trial design, predict the completion outcome and termination type (if applicable).